Recent News

• 02.19.2026 - Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
• 01.26.2026 - Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
• 01.13.2026 - Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
• 12.17.2025 - Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients

Recent Filings

• 02.19.2026 - EX-99.1 EX-99.1
• 02.19.2026 - 8-K Current report
• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.12.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.11.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.26.2026 - EX-99.1 EX-99.1
• 01.26.2026 - 8-K Current report
• 01.16.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.13.2026 - 8-K Current report